The European Commission (EC) has granted approval to Novartis' Kisqali (ribociclib), plus an aromatase inhibitor to treat ...

Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence: Basel Thursday, November 28, 2024, 09: ...

Novartis (NVS) announced that the European Commission, EC, has approved Kisqali in combination with an aromatase inhibitor, AI, for the ...

Novartis announced today that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone ...

The European Commission has cleared use of CDK4/6 inhibitor Kisqali (ribociclib) to reduce the risk of recurrence in patients ...

(RTTNews) - Novartis (NVS) said that the European Commission has approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor ...

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node ...

No bias, but Jon Jones is not Tom Aspinall's GOAT. In an interview with Jon Bernard Kairouz, Aspinall (15-3 MMA, 8-1 UFC) ...

Aromatase inhibitors, such as anastrozole, have been used off-label to increase height in children with short stature; however, few studies have investigated the use of aromatase inhibitors in ...

Mereo BioPharma targets osteogenesis imperfecta market growth with setrusumab. Discover why MREO stock is well-positioned for ...